News: MedPharm Shortlisted for Two CPHI Pharma Awards

MedPharm is pleased to announce that it has been selected as a finalist in two CPHI Pharma Award Categories.

MedPharm’s unique MedSpray® Aerosol Technology was shortlisted for the Finished Formulation category, and our MedCast model was shortlisted in the Drug Delivery Device Innovation category.


MedSpray® is a patented formulation technology specifically developed by MedPharm for a range of applications. It leaves a film on the skin or another tissue surface and is thermodynamically optimized to maximize the permeation and penetration of the API through the tissue. This benefits patients by offering the long-term dosing of a product from a clear “patch” that is conveniently applied as a spray from a can. MedSpray® has brought to the market a proprietary technology to address drug delivery challenges while successfully providing a cosmetically elegant and convenient way to apply drugs for the patient. To learn more about the advantages of MedSpray®, download our info sheet.


MedCast is a 3D-printed model of the nasal cavity that was developed by MedPharm, Ltd in 2022. The model was designed using actual cranial CT scans and aids in the assessment of a drug-device combination. MedCast allows developers to physically assess where a drug is deposited by the device within the targeted nasal regions. The model represents the functional regions of the nasal cavity.

About MedPharm

MedPharm is a global contract provider of topical and transdermal formulation development services specializing in reducing risk through unique, cost-effective, and industry-leading performance testing models. MedPharm offers innovative dermal/transdermal, respiratory, mucosal membrane, ophthalmic, and ungual product development solutions with locations in the United Kingdom and the United States. For more information, visit or follow us on LinkedIn